Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade

Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade

The HER2-enriched (HER2-E) subtype within HER2-positive (HER2+) breast cancer is highly addicted to the HER2 pathway. However, ∼20–60% of HER2+/HER2-E tumors do not achieve a complete response following anti-HER2 therapies. Here we evaluate gene expression data before, during and after neoadjuvant t...

Full description

Saved in:
Bibliographic Details
Main Authors: Brasó-Maristany, Fara, Griguolo, Gaia, Pascual, Tomás, Paré, Laia, Nuciforo, Paolo, Llombart-Cussac, Antonio, Bermejo, Begoña, Oliveira, Mafalda, Morales, Serafín, Martínez, Noelia, Vidal, Maria, Adamo, Barbara, Martínez, Olga, Pernas, Sonia, López, Rafael, Muñoz, Montserrat, Chic, Núria, Galván, Patricia, Garau, Isabel, Manso, Luis, Alarcón, Jesús, Martínez, Eduardo, Gregorio, Sara, Gomis, Roger R., Villagrasa, Patricia, Cortés, Javier, Ciruelos, Eva, Prat, Aleix
Format: Text
Language:English
Published: Nature Publishing Group UK 2020
Subjects:
Article
Online Access:https://pmc.ncbi.nlm.nih.gov/articles/PMC6971277/
https://pubmed.ncbi.nlm.nih.gov/31959756
http://dx.doi.org/10.1038/s41467-019-14111-3
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://pmc.ncbi.nlm.nih.gov/articles/PMC6971277/
https://pubmed.ncbi.nlm.nih.gov/31959756
http://dx.doi.org/10.1038/s41467-019-14111-3

Similar Items